Clinical Trial

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Study acronym: CAPTUR
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.
Protocol Amendment History 58 amendments
This ClinicalTrials.gov record has been amended 58 times since 2017-09-28; most recent amendment 2026-03-24.
Status change: Not Yet Recruiting → Recruiting 2018-03-15
Trial Details
NCT Number NCT03297606
Lead Sponsor Canadian Cancer Trials Group
Collaborators: AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Pfizer, Seagen Inc.
Conditions Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Enrollment 720 participants
Start Date 2018-03-23
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-27